Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 18, 2009

Asubio Pharma Using Genedata’s Biomarker Discovery Platform

  • Asubio Pharma is using the Genedata’s  Genedata Expressionist® system to support its compound profiling and biomarker discovery process. The Expressionist module Analyst is being used as an ultra-high-throughput framework for integrated statistical analysis for biomarker discovery.
    Analyst features visualizers and statistical algorithms to integratively analyze data from different omics technologies. Powered by a flexible workflow system and designed to analyze over one billion data points in real-time, Analyst can accommodate both in-house and public domain algorithms for statistical analysis, according to Genedata.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »